Citius OncologyCTOR -6.07%10 EBIT per Share is $-0.46 as of Mar. 2026. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 808 Drug Manufacturers companies, Citius Oncology ranks worse than 97.65% on this metric.
Citius Oncology's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.27.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.46.
During the past 3 years, the average EBIT per Share Growth Rate was -67.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Citius Oncology's EBIT per Share or its related term are showing as below:
CTOR'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -67.8 Med: -67.8 Max: -67.8
Current: -67.8
During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Citius Oncology was -67.80% per year. The lowest was -67.80% per year. And the median was -67.80% per year.
CTOR's 3-Year EBIT Growth Rate is ranked worse than 97.65% of 808
companies
in the Drug Manufacturers industry
Industry Median: 7.65
vs CTOR: -67.80
Citius Oncology's EBIT for the
three
months ended in Mar. 2026 was $-26.81 Mil.
Citius Oncology (NAS:CTOR) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Citius Oncology EBIT per Share Related Terms
Citius Oncology EBIT per Share Historical Data
* Premium members only.
The historical data trend for Citius Oncology's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.46
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Citius Oncology (CTOR) has a EBIT per Share of $-0.46 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Citius Oncology and its competitors. According to the industry distribution chart, Citius Oncology ranks #789 out of 808 companies in the Drug Manufacturers industry, placing it in the top 97.6%.
Is Citius Oncology's EBIT per Share too high?
Citius Oncology's current EBIT per Share is $-0.46. Based on the distribution chart, Citius Oncology ranks #789 out of 808 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's EBIT per Share compare to INCR and TLPH?
According to the Drug Manufacturers industry distribution chart, Citius Oncology ranks #789 out of 808 companies for EBIT per Share. This places Citius Oncology in the lower half of its industry. The industry median EBIT per Share is 7.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.65, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Citius Oncology and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citius Oncology's current EBIT per Share is $-0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current EBIT per Share of $-0.46. The current EBIT per Share is $-0.46. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Citius Oncology (CTOR), the current EBIT per Share is $-0.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score
Get the complete analysis for CTOR
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTOR has been successfully added to your 
